Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAT2 | Q10469 | 2/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.32 |
| ▸ | PLAU | P00749 | 4/20 | 0.30 |
| ▸ | PLG | P00747 | 3/20 | 0.30 |
| ▸ | PLAT | P00750 | 3/20 | 0.30 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12573695 | 1.00 | MGAT2 (0.33) | MGAT2DGAT1SIRT2MEN1RAB9A | |
| SCHEMBL29910207 | 1.00 | MGAT2 (0.33) | MGAT2DGAT1SIRT2MEN1RAB9A | |
| SCHEMBL1333836 | 1.00 | MGAT2 (0.33) | MGAT2DGAT1SIRT2MEN1RAB9A | |
| SCHEMBL29910222 | 1.00 | MGAT2 (0.33) | MGAT2DGAT1SIRT2MEN1RAB9A | |
| SCHEMBL12573700 | 0.94 | MAPT (0.35) | SIRT2MEN1RAB9AKMT2A | |
| SCHEMBL1333729 | 0.94 | CTSL (0.34) | SIRT2MEN1RAB9AKMT2AMAPK14 | |
| SCHEMBL1333587 | 0.94 | MAPT (0.35) | SIRT2MEN1RAB9AKMT2A | |
| SCHEMBL30914179 | 0.93 | MGAT2 (0.32) | MGAT2DGAT1SIRT2MEN1RAB9A | |
| SCHEMBL1332469 | 0.93 | MGAT2 (0.32) | MGAT2DGAT1SIRT2MEN1RAB9A | |
| SCHEMBL1333043 | 0.91 | CTSL (0.34) | SIRT2MEN1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2652552-B9 | PHOTOCHROMIC COMPOUNDS AND COMPOSITIONS | TRANSITIONS OPTICAL INC (US) | 2016-02-17 | — | — | EP | claimed |
| EP-2652552-B1 | PHOTOCHROMIC COMPOUNDS AND COMPOSITIONS | TRANSITIONS OPTICAL INC (US) | 2015-09-02 | — | — | EP | claimed |
| US-8545984-B2 | Photochromic compounds and compositions | TRANSITIONS OPTICAL, INC. (US) | 2013-10-01 | — | — | US | claimed |
| US-20110129678-A1 | Photochromic compounds and compositions | TRANSITIONS OPTICAL, INC. (US) | 2011-06-02 | — | — | US | claimed |
| EP-2718755-B1 | POLARIZING PHOTOCHROMIC ARTICLES | TRANSITIONS OPTICAL INC (US) | 2024-05-29 | — | — | EP | disclosed |
| EP-2718754-B1 | POLARIZING PHOTOCHROMIC ARTICLES | TRANSITIONS OPTICAL INC (US) | 2024-01-24 | — | — | EP | disclosed |
| EP-2969499-B1 | METHOD OF PREPARING PHOTOCHROMIC-DICHROIC FILMS HAVING REDUCED OPTICAL DISTORTION | TRANSITIONS OPTICAL INC (US) | 2021-12-08 | — | — | EP | disclosed |
| EP-2969468-B1 | METHOD OF PREPARING PHOTOCHROMIC-DICHROIC FILMS HAVING REDUCED OPTICAL DISTORTION | TRANSITIONS OPTICAL INC (US) | 2020-12-23 | — | — | EP | disclosed |
| EP-2652552-B9 | PHOTOCHROMIC COMPOUNDS AND COMPOSITIONS | TRANSITIONS OPTICAL INC (US) | 2016-02-17 | — | — | EP | disclosed |
| EP-2652552-B1 | PHOTOCHROMIC COMPOUNDS AND COMPOSITIONS | TRANSITIONS OPTICAL INC (US) | 2015-09-02 | — | — | EP | disclosed |
| US-20140265010-A1 | METHOD OF PREPARING PHOTOCHROMIC-DICHROIC FILMS HAVING REDUCED OPTICAL DISTORTION | TRANSITIONS OPTICAL LIMITED (IE) | 2014-09-18 | — | — | US | disclosed |
| US-20140264979-A1 | METHOD OF PREPARING PHOTOCHROMIC-DICHROIC FILMS HAVING REDUCED OPTICAL DISTORTION | TRANSITIONS OPTICAL LIMITED (IE) | 2014-09-18 | — | — | US | disclosed |
| US-8649081-B1 | Photochromic article having two at least partially crossed photochromic-dichroic layers | TRANSITIONS OPTICAL, INC. (US) | 2014-02-11 | — | — | US | disclosed |
| US-8582192-B2 | Polarizing photochromic articles | TRANSITIONS OPTICAL, INC. (US) | 2013-11-12 | — | — | US | disclosed |
| US-8545984-B2 | Photochromic compounds and compositions | TRANSITIONS OPTICAL, INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-8545015-B2 | Polarizing photochromic articles | TRANSITIONS OPTICAL, INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-20120120473-A1 | POLARIZING PHOTOCHROMIC ARTICLES | TRANSITIONS OPTICAL, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20110279883-A1 | POLARIZING PHOTOCHROMIC ARTICLES | TRANSITIONS OPTICAL, INC. (US) | 2011-11-17 | — | — | US | disclosed |
| US-20110129678-A1 | Photochromic compounds and compositions | TRANSITIONS OPTICAL, INC. (US) | 2011-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110129678-A1 | Photochromic compounds and compositions | CRY2, CRY1, PPOX | MGAT2 3604/4885DGAT1 3694/4885SIRT2 1159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.